Fujifilm to establish iPS cell manufacturing facility for clinical use in the USA

Fujifilm announced on December 20 that their subsidiary Fujifilm Cellular Dynamics will invest about 2.5 billion Yen (~20 million €) in Madison, Wisconsin.  Targets are regenerative medical products in the area of ​​age-related macular degeneration, retinal pigment degeneration, Parkinson’s disease, heart disease and cancer using high-quality iPS cells produced at this facility from 2019 on.

Fujifilm news release, December 20, 2018

 


Fujifilm to establish iPS cell manufacturing facility for clinical use in the USA
Scroll to top